Download PDF
Dtsch Med Wochenschr 2016; 141(08): 550-555
DOI: 10.1055/s-0042-100028
Dossier
Kollagenosen
© Georg Thieme Verlag KG Stuttgart · New York

Systemische Sklerose

Systemic sclerosis
Susanne Schinke
1   Klinik für Rheumatologie, Universität zu Lübeck
,
Gabriela Riemekasten
1   Klinik für Rheumatologie, Universität zu Lübeck
› Author Affiliations
Further Information

Publication History

Publication Date:
14 April 2016 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die systemische Sklerose stellt aufgrund ihrer zahlreichen Organmanifestation und ihrem Einfluss auf die Lebensqualität und Morbidität eine große Herausforderung dar. Lungenfibrose, pulmonale arterielle Hypertonie (PAH) und kardiale Manifestationen bestimmen die krankheitsbezogene Mortalität. Die Patienten weisen zudem eine Vielzahl von Komorbiditäten wie Mangelernährung, Depression, Osteoporose und ein erhöhtes Risiko für kardiovaskuläre Erkrankungen auf, welche erkannt und therapiert werden sollten. Das frühzeitige Erfassen und die Quantifizierung von Schäden sind neben der frühen und intensiven Therapie ein Schlüssel für den Therapieerfolg. Die Entdeckung von pathogenetisch bedeutsamen Autoantikörpern und die Kenntnis, dass intensive immunsuppressive und vasoaktive Therapien erfolgreich sind, sind wesentliche Fortschritte. Derzeit werden verschiedene Forschungsansätze überprüft. Therapien mit Biologika erscheinen erfolgversprechend und könnten künftig zur Zulassung führen.

Abstract

Systemic sclerosis is a challenging and heterogeneous disease due to the involvement of multiple organs and the high impact on morbidity and quality of life. Lung fibrosis, pulmonary arterial hypertension, and cardiac manifestations are main causes of systemic sclerosis-related deaths. In addition, patients suffer from a various range of co-morbidities such as malnutrition, depression, osteoporosis, malignancies, which are increased in these patients and have to be identified and treated. Early assessment of organ damage is a key to therapeutic success. The discovery of pathogenic autoantibodies combined with increased evidence of effective immunosuppressive and vasoactive treatment strategies are major developments in the therapy of the disease. At present, several clinical studies are ongoing and some of the biological therapies are promising.

Schlüsselwörter

Systemische Sklerose - Lungenfibrose - Angiotensin-Rezeptor-Autoantikörper - Endothelin-Rezeptor-Autoantikörper - Biologika - vasoaktive Therapie - Sklerodermie

Keywords

scleroderma - systemic sclerosis - lung fibrosis - vasoactive therapy - biologicals - angiotensin 1 receptor antibody - endothelin receptor antibody
 

  • Literatur

  • 1 Andréasson K, Saxne T, Bergknut C et al. Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria. Ann Rheum Dis 2014; 73: 1788-1792
    CrossrefPubMedGoogle Scholar
  • 2 van den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology / European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-2747
    CrossrefPubMedGoogle Scholar
  • 3 Tyndall A, Fistarol S. The differential diagnosis of systemic sclerosis. Curr Opin Rheumatol 2013; 25: 692-699
    CrossrefPubMedGoogle Scholar
  • 4 van Laar JM, Farge D, Sont JK et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014; 311: 2490-2498
    CrossrefPubMedGoogle Scholar
  • 5 Tashkin DP, Elashoff R, Clements PJ et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006; 354: 2655-2666
    PubMedGoogle Scholar
  • 6 Iudici M, Cuomo G, Vettori S et al. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders. Semin Arthritis Rheum 2015; 44: 437-444
    CrossrefPubMedGoogle Scholar
  • 7 Assassi S, Mayes MD. What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis?. Curr Opin Rheumatol 2013; 25: 686-691
    CrossrefPubMedGoogle Scholar
  • 8 Becker MO, Brückner C, Scherer HU et al. The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study. Ann Rheum Dis 2011; 70: 1340-1341
    CrossrefPubMedGoogle Scholar
  • 9 Kill A, Tabeling C, Undeutsch R et al. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther 2014; 16: R29
    CrossrefPubMedGoogle Scholar
  • 10 Becker MO, Kill A, Kutsche M et al. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med. 2014; 190: 808-817
    CrossrefPubMedGoogle Scholar
  • 11 Giuggioli D, Lumetti F, Colaci M et al. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev. 2015; 14: 1072-1078
    PubMedGoogle Scholar
  • 12 Riemekasten G, Philippe A, Näther M et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011; 70: 530-536
    CrossrefPubMedGoogle Scholar
  • 13 Günther J, Kill A, Becker MO et al. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res Ther 2014; 16: R65
    CrossrefPubMedGoogle Scholar
  • 14 LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205
    PubMedGoogle Scholar
  • 15 Hanitsch LG, Burmester GR, Witt C et al. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register. Rheumatology 2009; 48: 70-73
    PubMedGoogle Scholar
  • 16 Coghlan JG, Denton CP, Grünig E et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73: 1340-1349
    CrossrefPubMedGoogle Scholar
  • 17 Humbert M, Yaici A, de Groote P et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522-3530
    CrossrefPubMedGoogle Scholar
  • 18 Wirz EG, Jaeger VK, Allanore Y et al. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis 2015; pii annrheumdis-2015–207271
    PubMedGoogle Scholar
  • 19 Chung WS, Lin CL, Sung FC et al. Systemic sclerosis increases the risks of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Rheumatology 2014; 53: 1639-1645
    CrossrefPubMedGoogle Scholar
  • 20 Krause L, Becker MO, Brueckner CS et al. Nutritional status as marker for disease activity and severity predicting mortality in patients with systemic sclerosis. Ann Rheum Dis. 2010; 69: 1951-1957
    CrossrefPubMedGoogle Scholar
  • 21 Marasini B, Conciato L, Belloli L et al. Systemic sclerosis and cancer. Int J Immunopathol Pharmacol 2009; 22: 573-578
    PubMedGoogle Scholar
  • 22 Matucci-Cerinic M, Krieg T, Guillevin L et al. Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. Ann Rheum Dis 2015; pii annrheumdis-2015–208121
    PubMedGoogle Scholar
  • 23 Riemekasten G, Hoffmann U, Sunderkötter C et al. Management of digital ulcers in patients with systemic sclerosis. Dtsch Med Wochenschr. 2012; 137: 34-40
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Kowal-Bielecka O, Landewé R, Avouac J et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620-628
    CrossrefPubMedGoogle Scholar
  • 25 Roustit M, Blaise S, Allanore Y et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud‘s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013; 72: 1696-1699
    CrossrefPubMedGoogle Scholar
  • 26 Hachulla E, Hatron PY, Carpentier P et al. SEDUCE study group. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis 2015; pii annrheumdis-2014–207001
    PubMedGoogle Scholar
  • 27 de Paoli FV, Nielsen BD, Rasmussen F et al. Abatacept induces clinical improvement in patients with severe systemic sclerosis. Scand J Rheumatol 2014; 43: 342-345
    CrossrefPubMedGoogle Scholar
  • 28 Moazedi-Fuerst FC, Kielhauser SM, Bodo K et al. Dosage of rituximab in systemic sclerosis: 2-year results of five cases. Clin Exp Dermatol 2015; 40: 211-212
    CrossrefPubMedGoogle Scholar
  • 29 Mok CC, Kwok CL, Ho LY et al. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum. 2011; 63: 1182-1189
    CrossrefPubMedGoogle Scholar
  • 30 Tyndall AJ, Bannert B, Vonk M et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-1815
    CrossrefPubMedGoogle Scholar